US EditionDonald Trump Threatens to Double Taxes on Australia's Second Biggest Export
AUSTRALIA, JUL 8 – President Trump plans a 200% tariff on Australian pharmaceuticals with a 12-18 month grace period for manufacturers to relocate production to the US, officials said.
- Donald Trump has threatened a possible 200 percent tariff on pharmaceuticals from Australia, one of its major exports to the U.S., according to Elizabeth de Somer, chief executive of Medicines Australia.
- Elizabeth de Somer stated that the proposed tariffs are causing uncertainty regarding their implementation, as they are awaiting a U.S. Department of Commerce investigation.
- Greens senator Nick McKim criticized Donald Trump, urging the Australian government to protect affordable medicines for families.
- Bridget McKenzie highlighted bipartisan support for the Pharmaceutical Benefits Scheme, emphasizing its importance to accessing medicines amid Trump's tariff threats.
Insights by Ground AI
Does this summary seem wrong?
17 Articles
17 Articles
The Straits Times+2 Reposted by 2 other sources
Australia 'urgently seeking' details on Trump drug tariff plan
Australia is “urgently seeking more details” on US President Donald Trump’s threat to raise tariffs up to 200 per cent on pharmaceutical imports, Australian Treasurer Jim Chalmers said on July 9.
·Singapore
Read Full Article
Chalmers Responds to Trump’s 200 Percent Pharmaceutical Tariff Threat
Treasurer Jim Chalmers has said the Labor government will not make concessions on the Pharmaceutical Benefits Scheme (PBS), despite the looming threat of new U.S. tariffs on Australian pharmaceuticals. On July 8 (Washington time), U.S. President Donald Trump announced plans to impose tariffs of up to 200 percent on pharmaceuticals imported into the United States, along with a 50 percent tariff on copper. Amid concerns over the potential impact o…
·New York, United States
Read Full Article
Coverage Details
Total News Sources17
Leaning Left3Leaning Right5Center1Last UpdatedBias Distribution56% Right
Bias Distribution
- 56% of the sources lean Right
56% Right
L 33%
11%
R 56%
Factuality
To view factuality data please Upgrade to Premium
